Needham & Company Starts �terna Zentaris (AEZS) at Buy; Three Late-Stage Trials, Three Partners, and Three Potential Stock Catalysts

Needham & Company initiates coverage on Æterna Zentaris (NASDAQ: AEZS) with a Buy.

Needham analyst says, "We believe the time is right for investors interested in small-cap biotech stocks to turn increasing attention to AEZS, given the Company’s pipeline progress in targeted cancer therapeutics as well as expected near-term events. We are initiating coverage with a Buy rating and a price target of $5: our valuation thesis includes a sum-of-the-parts calculation and comparables analysis...We believe the Company’s solid science platform has matured and includes perifosine (Phase 3 underway), AEZS-108 (Phase 3 planned), and AEZS-130 (Phase 3 underway)."

For more ratings news on Æterna Zentaris click here and for the rating history of Æterna Zentaris click here.

Shares of Æterna Zentaris closed at $2.37 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Needham Starts Pulse Biosciences (PLSE) at Buy
• Gemini Space Station (GEMI) PT Lowered to $6 at Needham
• Globant S.A. (GLOB) PT Lowered to $45 at Needham